Promising Findings on MS Medications and Breastfeeding
A preliminary study released on March 4, 2024, offers hopeful news for mothers with multiple sclerosis (MS) who rely on monoclonal antibody treatments while breastfeeding. The research, to be presented at the American Academy of Neurology’s 76th Annual Meeting, explored the impact of four MS treatments—natalizumab, ocrelizumab, rituximab, and ofatumumab—on infants exposed through breast milk. The findings suggest that these infants, observed over three years, showed no developmental issues compared to those whose mothers abstained from these medications while nursing.
Managing MS During Childbearing Years
As MS typically affects women during their reproductive years, managing the disease around pregnancy and breastfeeding presents unique challenges. Although monoclonal antibodies are generally discouraged during breastfeeding, some mothers need to resume treatment soon after childbirth to reduce the risk of MS relapses. Understanding the safety of these medications for infants exposed via breast milk is crucial for balancing maternal health with the child’s well-being.
Encouraging Study Results with a Call for Continued Research
Led by Dr. Kerstin Hellwig of Ruhr University in Germany, the study tracked 183 infants exposed to monoclonal antibodies through breastfeeding. Researchers assessed hospital visits, antibiotic use, growth milestones, and overall health in these infants compared to a control group. Although the results were promising, indicating no major developmental concerns, the study notes that only a third of the infants were tracked for the entire three-year period, underscoring the need for further research to confirm long-term safety.